Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Feature

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Closely-held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every...

September 17, 2024

Feature

Model Medicines innovates by bringing together data science and biology to develop drugs

Closely-held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at...

September 3, 2024

Feature

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...

August 20, 2024

NEWS

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Model Medicines innovates by bringing together data science and biology to develop drugs

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

NEWS

Perimeter completes patient enrollment for pivotal trial evaluating next-gen OCT B-Series with ImgAssist AI in breast cancer surgery

Eupraxia expands Amanda Malone’s leadership role and names Rahul Sarugaser as EVP, corporate development

Valerio acquires oncology biotech, Emglev

IRLAB enrolls last patient in trial of Pirepemat for Parkinson’s

Roberto Bellini wins 2024 Bloom Burton Award

Beyond Air and TrillaMed deploy LungFit PH into U.S. Natal Hospital Guam NICU

Pasithea announces preliminary Phase 1 data for study of PAS-004 in advanced cancer

NanoViricides obtains ROFR for all antiviral drug treatments from TheraCour

BioRestorative’s IFATS presentation features ThermoStem’s potential to deliver a superior efficacy and tolerability profile over GLP-1 drugs

Just a few of the companies we’ve highlighted along the way

General

More